Atibuclimab Biosimilar – Anti-CD14 mAb – Research Grade from ProteoGenix; catalogue PX-TA1811; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Atibuclimab Biosimilar, also known as Anti-CD14 mAb, is a monoclonal antibody that has gained attention in the field of immunotherapy due to its potential as a therapeutic agent for various diseases. In this article, we will explore the structure, activity, and application of Atibuclimab Biosimilar in research grade.
Atibuclimab Biosimilar is a recombinant humanized monoclonal antibody that targets the CD14 protein. It is composed of two heavy chains and two light chains, each containing specific domains that are essential for its function. The heavy chain consists of a variable region, which recognizes and binds to the CD14 protein, and a constant region, which is responsible for the effector functions of the antibody. The light chain also contains a variable region and a constant region, which contribute to the overall stability and specificity of the antibody.
Atibuclimab Biosimilar specifically targets the CD14 protein, which is a co-receptor for Toll-like receptors (TLRs) and plays a crucial role in the innate immune response. By binding to CD14, Atibuclimab Biosimilar blocks the activation of TLRs, thereby inhibiting the downstream signaling pathways involved in inflammation and immune response. This mechanism of action makes Atibuclimab Biosimilar a promising therapeutic agent for diseases characterized by excessive inflammation, such as sepsis, rheumatoid arthritis, and inflammatory bowel disease.
Atibuclimab Biosimilar is currently being studied as a potential treatment for various diseases, with a focus on its anti-inflammatory properties. In preclinical studies, it has shown promising results in reducing inflammation and improving disease outcomes in animal models of sepsis, rheumatoid arthritis, and inflammatory bowel disease. Additionally, Atibuclimab Biosimilar has been shown to have a good safety profile in these studies, making it a potentially safe and effective treatment option for patients.
CD14 is a glycosylphosphatidylinositol (GPI)-anchored protein that is expressed on the surface of various immune cells, including monocytes, macrophages, and dendritic cells. It acts as a co-receptor for TLRs, which are key players in the innate immune response. CD14 plays a critical role in the recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by TLRs, leading to the activation of immune cells and the production of pro-inflammatory cytokines. However, excessive activation of TLRs and subsequent inflammation can contribute to the development and progression of various diseases. By targeting CD14, Atibuclimab Biosimilar can modulate the activity of TLRs and reduce inflammation, making it a potential therapeutic target for diseases characterized by dysregulated immune response.
Atibuclimab Biosimilar, also known as Anti-CD14 mAb, is a promising monoclonal antibody that targets the CD14 protein and has shown potential as a therapeutic agent for various diseases. Its structure, activity, and application make it a promising candidate for the treatment of diseases characterized by excessive inflammation. Further research and clinical trials are needed to fully understand the potential of Atibuclimab Biosimilar and its role in immunotherapy.
ProteoGenix catalogue number PX-TA1811. For research use only.
Target: Atibuclimab Biosimilar – Anti-CD14 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Atibuclimab Biosimilar – Anti-CD14 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
